• Alnylam Pharmaceuticals announced the publication of its 2025 Corporate Responsibility Report, outlining a Scope 1 and Scope 2 GHG emissions reduction framework through 2030, backed by an independent third-party review of its GHG inventory and methodology.
• Patient access initiatives cited include a new Patient Advisory Council, nearly doubling the size of its Case Management team, nearly doubling the size of its Access & Reimbursement teams, and the release of quantitative and qualitative metrics tied to its access strategy.
• Philanthropy disclosures include a two-year USD 2 million commitment under the Alnylam Challengers program to support Care Navigators in underserved Boston communities via partnerships with Boston Children’s Hospital, Boston Medical Center, and Whittier Street Health Center.
• The report is posted at https://www.alnylam.com/sites/default/files/pdfs/alnylam-cr-report-2025.pdf.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605190830BIZWIRE_USPR_____20260519_BW990338) on May 19, 2026, and is solely responsible for the information contained therein.